Clinical Trial Update: A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma [Phase 1]

View source ↗

Summary

Phase 1 double-blind, placebo-controlled study evaluating briquilimab in allergic asthma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Asthma

Drugs mentioned

• Briquilimab

Snippet

Sponsor: Jasper Therapeutics, Inc. | Conditions: Allergic Asthma | Phase 1 | Status: TERMINATED